V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Pfizer Executive Compensation (FY25)

PFE · New York, NY · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Albert Bourla
Latest say-on-pay support
=
April 23, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Pfizer

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): April 27, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Pfizer brief$1,500Get the executive brief
Velarion Member, one year
407 figures on this page: 401 cited to the filing that reported them, 6 calculated from figures it prints. See the citations

More on Pfizer

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Albert Bourla: $24,648,727 → $27,585,301 (11.9% higher)
Say-on-pay support: 54.7% → 88.0% (33.3 points higher)
CEO pay ratio: 269:1 → 277:1 (3.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Pfizer's chief executive and what were they paid?
Albert Bourla was paid $27,585,301 in total compensation as Chairman and Chief Executive Officer for fiscal 2025. Compared with the $24,648,727 reported for fiscal 2024, Bourla's total was 11.9% higher.
What was Pfizer's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 88.0% of votes cast for or against in favor at the meeting held April 23, 2026.
Which companies are in Pfizer's peer group?
The disclosed peer group includes 3M Company, Abbott Laboratories, Caterpillar Inc., Chevron Corporation and Comcast Corporation, among others. The Pharmaceutical Peers names AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company and Eli Lilly and Company, among others.
What is Pfizer's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 277:1, against median employee compensation of $99,631.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Albert Bourla
Chairman and Chief Executive Officer
◇—◇◇◇◇◇◇
David Denton
Chief Financial Officer, Executive Vice President
◇◇◇◇◇—◇◇
William Pao
Chief Development Officer, EVP
◇◇◇—◇—◇◇
Mikael Dolsten
Chief Scientific Officer, President, Pfizer Research & Development
◇—◇◇◇—◇◇
Frank D’Amelio
Former Chief Financial Officer, EVP
Departed during or after this year
◇—◇◇◇—◇◇
Angela Hwang
Chief Commercial Officer and President, Global Biopharmaceuticals Business
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Albert Bourla
Chairman and Chief Executive Officer
◇—◇◇—◇◇◇
Mikael Dolsten
Chief Scientific Officer, President, Pfizer Research & Development
◇—◇◇—◇◇◇
Angela Hwang
Former Chief Commercial Officer and President, Global Biopharmaceuticals Business
Departed during or after this year
◇—◇◇—◇◇◇
William Pao
Former Chief Development Officer, Executive Vice President
Departed during or after this year
◇◇◇◇——◇◇
Douglas Lankler
Chief Legal Officer, Executive Vice President
◇—◇◇—◇◇◇
Aamir Malik
Chief U.S. Commercial Officer, Executive Vice President
◇—◇◇——◇◇
David Denton
Chief Financial Officer, Executive Vice President
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Albert Bourla
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Mikael Dolsten
Chief Scientific Officer, President, Pfizer Research & Development
◇—◇◇◇—◇◇
Aamir Malik
Chief U.S. Commercial Officer, Executive Vice President
◇—◇◇◇—◇◇
David Denton
Chief Financial Officer, Executive Vice President
◇—◇◇◇—◇◇
Chris Boshoff
Chief Scientific Officer and President, Research & Development
◇—◇◇◇—◇◇
Douglas Lankler
Chief Legal Officer, Executive Vice President
◇—◇◇◇◇◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Albert Bourla
Chairman and Chief Executive Officer
◇—◇◇◇◇◇◇
Chris Boshoff
Chief Scientific Officer and President, Research & Development
◇—◇◇◇—◇◇
David Denton
Chief Financial Officer, Executive Vice President
◇—◇◇◇—◇◇
Aamir Malik
Chief U.S. Commercial Officer, Executive Vice President
◇—◇◇◇—◇◇
Douglas Lankler
Chief Legal Officer, Executive Vice President
◇—◇◇◇◇◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Aamir MalikPSU◇◇◇—◇—◇
Aamir MalikRSU◇——◇——◇
Albert BourlaPSU◇◇◇—◇—◇
Albert BourlaRSU◇——◇——◇
Chris BoshoffPSU◇◇◇—◇—◇
Chris BoshoffPSU◇◇◇—◇—◇
Chris BoshoffRSU◇——◇——◇
David DentonPSU◇◇◇—◇—◇
David DentonRSU◇——◇——◇
Douglas LanklerPSU◇◇◇—◇—◇
Douglas LanklerRSU◇——◇——◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Chris BoshoffPSU◇◇——
Option◇—◇3/4/2030
PSU◇◇——
Option◇—◇2/27/2031
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/23/2030
Option◇—◇2/28/2026
Option◇—◇2/27/2027
Option◇—◇2/24/2029
PSU◇◇——
Option◇—◇2/25/2028
Option◇—◇2/27/2029
David DentonPSU◇◇——
PSU◇◇——
Option◇—◇2/27/2031
Option◇—◇2/23/2030
Option◇—◇2/23/2030
PSU◇◇——
Option◇—◇5/31/2029
Option◇—◇5/31/2029
Option◇—◇2/27/2029
PSU◇◇——
Option◇—◇3/4/2030
Douglas LanklerOption◇—◇2/24/2029
Option◇—◇3/4/2030
PSU◇◇——
PSU◇◇——
Option◇—◇2/25/2028
Option◇—◇2/23/2030
Option◇—◇2/28/2026
Option◇—◇2/27/2027
Option◇—◇2/27/2029
PSU◇◇——
Option◇—◇2/28/2029
Option◇—◇2/23/2030
Option◇—◇2/27/2031
Option◇—◇2/25/2026
PSU◇◇——
Option◇—◇2/24/2029
Option◇—◇2/28/2029
Aamir MalikPSU◇◇——
Option◇—◇2/23/2030
Option◇—◇2/27/2029
PSU◇◇——
Option◇—◇2/24/2029
PSU◇◇——
PSU◇◇——
Option◇—◇2/24/2029
Option◇—◇2/23/2030
Option◇—◇2/27/2031
Option◇—◇3/4/2030
Albert BourlaOption◇—◇2/24/2029
Option◇—◇2/24/2029
Option◇—◇2/23/2030
Option◇—◇2/27/2031
PSU◇◇——
Option◇—◇2/27/2027
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/28/2026
Option◇—◇2/23/2030
Option◇—◇2/27/2029
Option◇—◇3/4/2030
Option◇—◇2/25/2026
Option◇—◇2/25/2028
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Suzanne Nora Johnson
◇◇———◇◇
Shantanu Narayen
Lead independent director
◇◇————◇
Joseph J. Echevarria
◇◇———◇◇
Scott Gottlieb
◇◇———◇◇
James C. Smith
◇◇————◇
Susan Desmond-Hellmann
◇◇————◇
James Quincey
◇◇———◇◇
Dan R. Littman
◇◇———◇◇
Cyrus Taraporevala
◇◇———◇◇
Susan Hockfield
◇◇———◇◇
Ronald E. Blaylock
◇◇————◇
Mortimer J. Buckley
◇◇————◇
Helen H. Hobbs
◇—————◇
Albert Bourla served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Equity is delivered as Pfizer Stock Units.
Stock ownership guideline: 5x annual cash retainer ($775,000)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 3M Company MMM
  • Abbott Laboratories ABT
  • Caterpillar Inc. CAT
  • Chevron Corporation CVX
  • Comcast Corporation CMCSA
  • ConocoPhillips COP
  • Danaher Corporation DHR
  • Honeywell International Inc. HON
  • International Business Machines Corporation IBM
  • Lockheed Martin Corporation LMT
  • Medtronic plc MDT
  • Mondelez International, Inc. MDLZ
  • PepsiCo, Inc. PEP
  • RTX Corporation RTX
  • The Boeing Company BA
  • The Coca-Cola Company KO
  • The Procter & Gamble Company PG
  • Thermo Fisher Scientific Inc. TMO
  • United Parcel Service, Inc. UPS
  • Verizon Communications Inc. VZ
Pharmaceutical Peers
  • AbbVie Inc. ABBV
  • Amgen Inc. AMGN
  • AstraZeneca PLC AZN
  • Bristol-Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Gilead Sciences, Inc. GILD
  • GSK plc GSK
  • Johnson & Johnson JNJ
  • Merck & Co., Inc. MRK
  • Novartis AG NVS
  • Roche Holding AG symbol not shown
  • Sanofi SNY

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 23, 2026=◇◇◇
2024April 24, 2025=◇◇◇
2023April 25, 2024=◇◇◇
2022April 27, 2023=◇◇◇
2021April 28, 2022=◇◇◇
2020April 22, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Albert Bourla (Chairman and Chief Executive Officer), FY2025 total compensation $27,585,301 (base salary $1,800,000) [exec_comp, SEC accession 0000078003-26-000033, filed 2026-03-12]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Pfizer files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Pfizer disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pfizer sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Pfizer's disclosed peer group is defensible, who names Pfizer back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
407 figures on this page: 401 cited to the filing that reported them, 6 calculated from figures it prints.
401 cited to the filing
6 calculated from the filing

Documents cited

  1. 0000078003-26-000044
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000078003-26-000033
    2025 Director Compensation Table · 2025 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE · CEO PAY RATIO · Compensation Tables · and 2 more sections
  3. 0000078003-25-000109
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000078003-25-000062
    Compensation Tables · SUMMARY COMPENSATION TABLE · Summary Compensation Table
  5. 0000078003-24-000101
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000078003-24-000068
    Compensation Tables · SUMMARY COMPENSATION TABLE
  7. 0001628280-23-014368
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000078003-23-000040
    Compensation Tables
  9. 0000078003-22-000066
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0000078003-21-000059
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pfizer executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PFE (accessed 2026).
Short form: data: Velarion

The paid brief for Pfizer

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pfizer and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Pfizer discloses

The companies named in PFE's own disclosed peer group.

3M CompanyAbbott LaboratoriesCaterpillar Inc.Chevron CorporationComcast CorporationConocoPhillipsDanaher CorporationHoneywell International Inc.International Business Machines CorporationLockheed Martin CorporationMedtronic plcMondelez International, Inc.PepsiCo, Inc.RTX CorporationThe Boeing CompanyThe Coca-Cola CompanyThe Procter & Gamble CompanyThermo Fisher Scientific Inc.United Parcel Service, Inc.Verizon Communications Inc.AbbVie Inc.Amgen Inc.Bristol-Myers Squibb CompanyEli Lilly and Company

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy